Health
Cancer Prevention
Pharmaceutical

Agenus

$2.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.09 (-3.01%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Agenus and other stocks, options, ETFs, and crypto commission-free!

About

Agenus Inc. Common Stock, also called Agenus, is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Read More Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

Employees
294
Headquarters
Lexington, Massachusetts
Founded
1994
Market Cap
347.99M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.56M
High Today
$3.01
Low Today
$2.85
Open Price
$2.98
Volume
1.14M
52 Week High
$5.34
52 Week Low
$1.54

Collections

Health
Cancer Prevention
Pharmaceutical
Medical
Biotechnology
Technology
US
North America

News

The Motley Fool21h

3 Top Growth Stocks to Buy Right Now

Growth stocks are known for their market-beating returns, which also explains why such stocks often command a premium in the stock market.

714
Seeking AlphaMar 14

Agenus Inc.'s (AGEN) CEO Garo Armen on Q4 2018 Results - Earnings Call Transcript

Agenus Inc. (NASDAQ:AGEN) Q4 2018 Results Earnings Conference Call March 14, 2019 8:30 AM ET Company Participants Jennifer Buell - Chief Operating Officer Garo Armen - Chairman and Chief Executive Officer Anna Wijatyk - Vice President of Clinical Development Christine Klaskin - Vice President of Finance & Principal Accounting Officer Conference Call Participants Matt Phipps - William Blair Operator Good morning ladies and gentlemen. Thank you for standing by and welcome to the Agenus Fourth Quarter...

0
Yahoo FinanceMar 14

Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up

Agenus Inc. AGEN announced that it has received $7.5 million in cash as milestone payment from Gilead Sciences GILD after the FDA accepted the company's investigational new drug (IND) application for AGEN1423. AGEN1423 is a first-in-class molecule, currently developed in partnership with Gilead as a potential treatment for cancer. Agenus is also eligible to receive additional milestones from Gilead in 2019 as well as in the future. Shares of Agenus were up almost 3.5% following this news on Wednesday. In ...

216

Earnings

-$0.40
-$0.35
-$0.29
-$0.24
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.28 per share
Actual
-$0.40 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.